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i. Abbreviations 
	
2-Keto-3-Deoxyoctonic acid (Kdo); 3-O-desacyl-4’-
Monophosphoryl Lipid A (MPL); Arterial Carbon Dioxide (PaCO2); 
Bacterial and Permeability-Increasing protein (BPI); Dimethyl 
Sulfoxide (DMSO); Disseminated Intravascular Coagulation 
(DIC); Endoplasmic Reticulum (ER); Enzyme-Linked 
Immunosorbent Assay (ELISA); Human Acute Monocytic Leukemia 
Cells (THP-1); Inhibitor of κB (IκB); Inhibitor of κB Kinase 
(IKK); Interleukin-1 Receptor-Associated Kinase 4 (IRAK4); 
Leucine-Rich Repeat Regions (LRR); Lipopolysaccharide (LPS); 
LPS Binding Protein (LBP); Membrane anchored CD14 (mCD14); 
Myeloid Differentiation primary response gene 88 (MyD88); 
Myeloid Differentiation protein-2 (MD-2); N-Methylmorpholine 
N-Oxide (NMO); Nitric Oxide (NO); Nuclear Factor κB (NFκB); 
Pathogen-Associated Molecular Patterns (PAMPs); Pattern 
Recognition Receptors (PRRs); Soluble CD14 (sCD14); Sterile 
α and HEAT-Armadillo Motif-containing protein (SARM); 
Systemic Inflammatory Response Syndrome (SIRS); 
Tetrapropylammonium Perruthenate (TPAP); TIR domain-
containing adapter Inducing IFN-β (TRIF); TIR domain-
containing Adapter Protein (TIRAP); Toll Interleukin-1 
Receptor (TIR); Toll-Like Receptor 4 (TLR4); Toll-Like 
Receptors (TLR); TRIF-Related Adapter Molecule (TRAM); 
Trimethylsilyl Bromide (TMSBr); Tumor Necrosis Factor α 
(TNFα) 
 
ii. Abstract 
 
 Systemic Inflammatory Response Syndrome (SIRS) is 
classified as an immune system response to an infectious 
state. If left untreated, SIRS leads to sepsis, septic shock, 
end-organ dysfunction, and death. As a patient progresses 
through these stages, associations of acute respiratory 
distress, disseminated intravascular coagulation, and acute 
renal failure persist, resulting in millions of deaths 
annually. Lipopolysaccharide (LPS), a bacterial endotoxin, is 
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released into the blood stream, triggering SIRS. LPS is found 
in the outer cell-wall of Gram-negative bacteria and is 
responsible for initiation of a devastating cytokine storm. 
One of the regions of LPS, lipid A, is a polyacylated 
glucosamine disaccharide that is primarily responsible for 
the pathological response of the immune system. LPS interacts 
with a plasma-LPS binding protein (LBP) via the lipid A 
region. LPS-LBP signals the CD14 receptor found on phagocytes 
and Toll-like receptors (TLR4), which results in a signaling 
pathway for inflammatory molecules like cytokines, TNFα, 
among numerous others. Antibiotic treatments alone prove 
insufficient; with numerous research data indicating 
increased bacterial resistance.  
 It has been demonstrated that compounds resembling the 
lipid A region can act as antagonist to LPS signaling and 
would de-activate the inflammatory cascade. Blocking this 
cascade of events, in conjunction with other known sepsis 
treatments, would prove beneficial to patient prognoses. 
Lipid A analogues have been developed which are antagonists 
of LPS signaling and do not activate the inflammatory cascade. 
The most interesting antagonists are the monosaccharides, 
which demonstrate that the glucosamine nitrogen can be 
replaced by oxygen and acyl groups can be replaced by more 
robust ethers.
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I. Introduction 
 
 
1. Immunopathogenesis 
 Our innate immunity has evolved into a complex system 
that elicits a response to pathogenic microbes to achieve a 
survival advantage. The immune response attempts to localize 
the infection and repair the damaged tissue. This is achieved 
by activation of circulating and fixed phagocytic cells and 
the production of pro-inflammatory and anti-inflammatory 
mediators. The balance between these mediators facilitates 
tissue repair, while simultaneously keeping the infection 
from spreading. When the inflammatory response extends beyond 
the infected tissues and becomes generalized, this balance is 
lost. The process to control infection then becomes 
uncontrolled and unregulated, leading to sepsis. 
 
2. Endotoxin 
 Near the turn of the 20th century, it was discovered that 
heat-killed Vibrio cholerae were intrinsically toxic as 
opposed to producing toxicity by secretion of a product. To 
	 7	
differentiate, toxicity from a secreted product became 
recognized as an exotoxin while the toxic components of 
bacteria themselves were termed endotoxins. After further 
characterizations, these heat-stable endotoxins became known 
as lipopolysaccharide (LPS) and are localized to the cell-
wall of Gram-negative bacteria. Gram-negative bacteria 
feature peptidoglycan that is encapsulated by two distinct 
lipid membranes (Figure 11). The cytosolic bilayer consists 
of conventional phosphoglycerides, whilst the outer membrane 
is profoundly distinctive. The outer membrane is an 
Figure 11 | Cell-wall of Gram-negative Bacteria.  
Organization of lipopolysaccharide, lipid A, lipoprotein, porins, 
peptidoglycan and phospholipid. The outer membrane is an asymmetric 
bilayer. The outer-leaflet of the outer membrane is highly 
distinctive due to the presence of lipopolysaccharide. The cytosolic 
bilayer consists of conventional phosphoglycerides.   
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asymmetric bilayer and LPS is the primary constituent of the 
outer leaflet, of which lipid A is an integral component.  
 Pyrogenic bacteria generate endotoxins that stimulate 
the release of inflammatory mediators, leading to fever and 
systemic effects of inflammation advancing to septicemia. LPS 
may be released from the membrane during bacterial growth or 
during treatment with antibiotics. Intriguingly, relatively 
low concentrations of LPS can act as an immune-modulator by 
inducing non-specific resistance to both bacterial and viral 
infections.2  
 
3. Sepsis 
 Sepsis is a highly complex, variable and multifactorial 
disease process caused by the over-exaggeration of the host’s 
response to endotoxin.3 Predominantly responsible for Gram-
negative bacteremia are Enterobacteriaceae and Pseudomonas, 
although other microorganisms can induce a similar response. 
Clinicians consider Gram-negative bacteremia as an 
idiosyncratic ailment due to its distinct clinical 
manifestations, epidemiology, pathogenesis, and treatment. 
Therefore, a consensus of the progression through stages of 
the illness was adopted by physicians. To start, systemic 
inflammatory response syndrome (SIRS) is classified as an 
immune system response to an infectious state and is evident 
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with at least two of the following patient indicators: (1) 
temperature greater than 38º C or less than 36º C; (2) heart 
rate greater than 90 beats per min; (3) tachypnea, which is 
defined as a respiratory rate greater than 20 breaths per 
minute coupled with an arterial carbon dioxide (PaCO2) less 
than 32 mmHg; (4) an alteration of white blood cell counts of 
greater than 12,000 cells/mm3, less than 4,000 cells/mm3, or  
greater than 10% immature neutrophils.3 Furthermore, severe  
sepsis is defined as illness complicated by hypoperfusion 
abnormalities like: lactic acidosis, oliguria, and/or mental 
status changes, eventually leading to hypotension. Septic 
shock is used to reference the illness when associated with 
Table 1. The 20 most expensive conditions treated in U.S. hospitals, all payers, 2013 
Rank CCS principal 
diagnosis category 
Aggregate hospital costs, 
$ millions 
National 
costs, % 
Number of 
hospital stays, 
thousands 
Hospital 
stays, % 
1 Septicemia  23,663 6.2 1,297 3.6 
2 Osteoarthritis 16,520 4.3 1,023 2.9 
3 Liveborn 13,287 3.5 3,765 10.6 
4 Device complications, 
implant or graft 
12,431 3.3 632 1.8 
5 Acute myocardial 
infarction 
12,092 3.2 602 1.7 
Table 15 | Epidemiology of Sepsis 
Abbreviation: CCS, Clinical Classifications Software 
Sources include: Agency for Healthcare Research and Quality (AHRQ), 
Center for Delivery, Organization, and Markets, Healthcare Cost and 
Utilization Project (HCUP), National Inpatient Sample (NIS), 2013 
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hypotension that is not responsive to fluid resuscitation. If 
left untreated, SIRS leads to sepsis, severe sepsis, septic 
shock, end-organ dysfunction, and death. As a patient 
progresses through these stages, associations of acute 
respiratory distress, disseminated intravascular coagulation 
(DIC), and acute renal failure persist,3 resulting in millions 
of deaths annually.4 In fact, sepsis is the leading cause of 
death in noncoronary intensive care units and amounts to as 
much as $24 billion in annual healthcare expenditures in the 
United States alone (Table 15).6 
 
4. Current Interventions for Sepsis 
 The treatment of Gram-negative bacteremia traditionally 
involves three basic principles. First is identification and 
management of primary sites of infection. Resolution of 
bacteremia may depend upon successful management of the loci 
of infection and rapid identification of microorganisms 
responsible by Gram staining and culture of inflammatory 
material such as blood, sputum, urine, cerebral spinal or 
synovial fluid, etc. Second, there is an ongoing assessment 
of physiological parameters with interventions to support 
vital organ perfusion. For instance, the presence of 
hypotension is first treated with fluid resuscitation to 
expand intravascular volume. Persistent hypotension is 
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treated with sympathomimetic amines including dopamine, 
dobutamine and isoproterenol. Levophed (norepinephrine) is an 
intense vasoconstrictor considered if the previous 
sympathomimetics are found ineffective. Third, the 
administration of intravenous antibiotic therapy appropriate 
for the spectrum of bacteria. However, this classical triad 
of treatments is not geared towards blocking the toxic effects 
of endotoxin, which are further exaggerated by bacterial 
lysis from antibiotic therapy. Consequently, antibiotics 
alone do not alleviate, but rather increase the toxic effects 
of LPS in the septicemic patient.7 The ensuing fluid 
administration and sympathomimetic treatments are merely 
supportive measures aimed to combat subsequent hemodynamic 
compromise from the overzealous host response. Whilst these 
treatments are necessary, future sepsis treatments should be 
spearheaded towards treating immunopathogenesis, not its 
symptoms.  
 Clearly, the pathophysiology of sepsis is 
extraordinarily complex. Exacerbating this complexity, 
patients that are susceptible to infection have many other 
medical conditions that affect their immune responsiveness 
and contribute to mortality. A distinct combination of 
therapies with a patient that is neutropenic (low neutrophils 
in bloodstream)8 may differ for adjunctive therapies in an 
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elderly patient with a perforated diverticulum (bulging sac 
on the colon wall).9 Presumably, an intervention with a single 
agent at a single time point in the progression of sepsis is 
unlikely to be effective. Advancement in treatments of sepsis 
may depend upon disrupting underlying mechanisms of 
immunopathogenesis responsible for tissue damage.  
 Corticosteroids have been researched as a potential 
adjuvant therapy due to their ability to attenuate the 
inflammatory response. However, in phase 3 clinical trials 
mortality rates of patients receiving corticosteroid 
treatment and a placebo were similar.10,11 Opioid receptor 
blockers such as naloxone demonstrated improved survival in 
animal studies, as did corticosteroids. Similarly, naloxone 
failed to show any significant difference in mortality rates 
in human trials.12  
 Neutralization of endotoxin could be an attractive 
treatment against Gram-negative bacteremia induced sepsis. 
Past studies in humans using antibodies to endotoxin by 
administering polyclonal antiserum raised against core 
polysaccharide and lipid A regions of LPS demonstrated 
significantly reduced mortality rates.13 However, the 
associated cost of producing antiserum coupled with the 
potential for transmission of infection prevented the 
widespread use of this treatment.  
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 An approach that would circumvent the complications of 
cost and transmission of infection could be the development 
of nontoxic lipid A analogues. In animal models, enhanced 
survival from Gram-negative bacteremia using lipid A 
analogues has been demonstrated.14 An in-depth analysis of the 
initial events in LPS-signaling is essential to develop a 
rational therapy directed at blocking LPS-induced sepsis. 
Additionally, illuminating the structural components of LPS 
responsible for immunopathogenesis is vital to identify 
therapeutic targets. 
 
II. Background 
 
A. Structure of LPS 
 Early attempts to elucidate the structure of LPS failed 
for many reasons. LPS is highly amphipathic and has an 
inherent tendency to aggregate through hydrophobic bonding or 
by crosslinking via ionic interactions. Mildly acidic 
conditions using trichloroacetic acid to extract and purify 
LPS was first performed by Boivin et. al. in the 1930s. 
However, LPS purified by the Boivin method was in effect a 
crude fraction containing many cell-wall contaminants. It was 
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not until later that Westphal and Luderitz et. al. developed 
an improved method for isolating endotoxin, which led to the 
LPS nomenclature.15 Today, modern mass spectrometry with 
matrix-assisted laser desorption and electrospray ionization 
has been pivotal for characterizing intricate details of LPS 
between species.16 Accordingly, LPS derived from all 
characterized Gram-negative bacteria are composed of three 
distinct regions, namely lipid A, core oligosaccharide and O-
antigen repeats (Figure 21). Lipid A contains a hydrophobic 
region that anchors LPS to the outer leaflet of the outer 
membrane. Distal to lipid A is a core oligosaccharide area 
consisting of sugar residues with multiple phosphoryl 
substituents, followed by a structurally diverse polymer 
Figure 21 | Structure of LPS. 
The three major regions of LPS are: O-polysaccharide, Core 
oligosaccharide, and lipid A. O-polysaccharide is highly 
variable, but the Core and lipid A regions are more conserved 
between Bacteria. The lipid A portion of LPS is responsible for 
endotoxicity. Hep, heptose; Kdo, 2-keto-3-deoxyoctonate; GlcN, 
glucosamine; P, phosphate.     
Repeating Subunits
n P
P
P
NH2 P
P
O-polysaccharide chain Core oligosaccharide Lipid A
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called O-antigen that is composed of repeat oligosaccharide 
units.16 Both core oligosaccharide and O-antigen are displayed 
on the surface of Gram-negative bacterial cells. The 
remaining surface of the outer leaflet of the outer membrane 
is taken up by proteins, while the inner leaflet contains 
conventional phosphoglycerides, mostly phosphatidyl-
ethanolamine/glycerol and cardiolipin.16 
 
 
1. The Core Region 
 The core region is more 
architecturally uniform than the 
outer O-antigenic region, 
exhibiting moderate interbacterial 
variability.17 The inner core 
contains characteristic components 
heptose and 2-keto-3-deoxyoctonic 
acid (Kdo). Predominantly, the 
inner core contains two or more Kdo 
residues and two or three L-
glycero-D-manno-heptose residues 
(Figure 316). The Kdo residue is 
positioned at the reducing end of 
the inner core and is linked to C-
Figure 316 | The Core 
region. 
The inner core usually 
consists of two Kdo and 
three L-glycero-D-manno-
heptose residues. The outer 
core is composed of 
conventional sugars such as 
glucose and/or galactose. 
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6’ of the two hexosamine (lipid A) residues. The L-glycerol-
D-manno-heptose residues are located on the other side of the 
short oligosaccharide inner core chain. Both Kdo and L-
glycerol-D-manno-heptose residues are unique to bacteria.18 
In contrast, the outer core region consists of commonly 
observed sugars and is more variable than the inner core. The 
outer core region is generally two or three residues long 
with one or more covalently bound polysaccharides as side 
chains19 (Figure 316). 
 
2. The O-antigen region 
 Attached at the terminal sugar of the core region, 
further extending extracellularly are repeating units of 
oligosaccharides comprising the O-antigen region. By 
position, it is the O-antigen region that encounters the hosts 
defense mechanisms during infection while also shielding the 
effects of antibiotic treatments. O-antigen also forms the 
basis of serotype classification of bacterial genera.20 It 
consists of zero to as many as 40 repetitive oligosaccharide 
subunits, which in turn contain two to seven monosaccharide 
residues.20 The inherent diversity of monosaccharides arising 
from alternative configurations, coupled with innumerable 
variability in glycosidic linkages, results in the O-antigen 
region being the most variable component of LPS, and unique 
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to individual bacterial strains. Significantly, when 
separated from the lipid A component of LPS, neither the O-
antigen nor the core polysaccharide exhibit endotoxic 
activity.20 
 
3. Lipid A 
 Lipid A is a distinct 
phosphoglycolipid and the fundamental 
backbone structure is highly conserved 
amongst bacteria (Figure 421).22 All 
contain D-gluco-configured pyranose 
hexosamine residues that are β (1➝6) 
linked dimers.16 Also, the disaccharide 
component consists of α-glycosidic and 
non-glycosidic phosphoryl substituents 
located at C-1 and C-4’. The 
phosphorylated disaccharide backbone 
contains ester or amide linkages at 
positions O-2, O-3, O-2’ and O-3’of 
(R)-3-hydroxy fatty acids, of which 
two are usually further acetylated.16  
Figure 421 | Lipid A 
Lipid A functions as an 
anchor by binding LPS 
to peptidoglycan with 
fatty acid chains. 
Fatty acids widely 
recognized include: 
caporic (C6), lauric 
(C12), myristic (C14), 
palmitic (C16), and 
steric (C18) acids.    
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 However, each Gram-negative bacterial species has unique 
structural features and composition for lipid A (Figure 523). 
Figure 523 | Lipid A from various bacterial species. 
Structural differences compared to the E. coli archetype arise 
from: the presence of phosphoryl substituents, degree of 
phosphorylation, and lipophilic chain lengths.   
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Fluctuations of the detailed structure emanate from: (1) the 
presence of phosphoryl substituents, such as a 4-amino-deoxy-
L-arabinose and/or phosphoethanolamine linked axial at C-1 or 
C-4’, (2) the degree of phosphorylation, (3) and importantly 
the highly variable nature of the lipids, with lipophilic 
chain lengths usually 6 to 18 carbon atoms in length. Also 
important are the type and position of the acyl groups. The 
acylation pattern of each hexosamine residue can have either 
a symmetric (3+3) or an asymmetric (4+2) distribution.22 
 Functionally, lipid A provides the anchor that binds LPS 
to the membrane with large numbers of saturated fatty acyl 
groups. This generates a gelatinous barrier of low fluidity 
and even impedes the infiltration of hydrophobic particles 
into the membrane. The two polysaccharide components interact 
with the extracellular environment and extend ~10 nm from the 
surface of the outer membrane. These heteropolysaccharide 
chains allow passage of small molecules for nutrient uptake, 
but are impermeable to larger molecules like proteins. This 
feature confines periplasmic proteins to prevent them from 
diffusing away. The barrier is additionally stabilized by 
LPS-associated cations that link adjacent molecules through 
salt bridges. Taken as a whole, the highly oriented and 
tightly cross-linked structure protects Gram-negative 
bacteria from a variety of host-defense molecules, thereby 
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permitting growth and survival within harsh environments or 
an infected host. 
 
B. The LPS Receptor Complex 
 Accurate recognition of pathogen-associated molecular 
patterns (PAMPs) by pattern recognition receptors (PRRs) is 
the crux of the innate immune response.24 An important 
receptor on the surface of immune cells such as 
monocytes/macrophages, neutrophils, B lymphocytes, myeloid 
dendritic and mast cells that recognizes LPS is toll-like 
receptor 4 (TLR4). As a homodimer, TLR4 requires the small 
myeloid differentiation protein-2 (MD-2) for recognition of 
LPS.24 Other key proteins such as LPS binding protein (LBP) 
and CD14 facilitate the presentation of LPS to the TLR4-MD-2 
Figure 624 | LPS receptor 
complex. 
TLR4 recognizes LPS at the surface of 
immune cells. Recognition is 
facilitated by MD-2, CD14 and LBP. MD-
2 associates with extracellular 
domains (A and B patches) of TLR4 and 
evokes sensitivity to LPS. LBP is a 
soluble shuttle protein that 
transfers LPS to the complex. CD14 
exists as soluble (sCD14) or membrane 
bound (mCD14). CD14 is a co-receptor 
that binds LPS transported by LBP and 
in turn relocates LPS to the TLR4-MD-
2 complex. LPB, lipid binding 
protein; TLR4, toll-like receptor 4; 
MD-2, myeloid differentiation protein 
2.        
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complex (Figure 624).24 Once activated, TLR4 mobilizes adapter 
molecules within the cytoplasm of cells to propagate a 
signal.24 In turn, the adapter molecules activate molecules 
within the cell to amplify the signal, which leads to the 
induction of genes that orchestrate the inflammatory 
response.  
 
1. LBP & CD14 
 Above critical micellar concentrations, LPS forms large 
aggregates in aqueous environments due to its inherent 
amphipathic nature. LBP is a soluble shuttle protein that 
avidly binds to LPS aggregates 
and facilitates the association 
between LPS and CD14.25 As a 
complex, LBP-CD14 enhance the 
detection of LPS by extracting 
and monomerizing it prior to 
presentation at the TLR4-MD-2 
complex.  
  LBP belongs to the lipid 
transfer family and to date its 
structure has not been reported. 
Bacterial and permeability-
increasing protein (BPI), 
Figure 726 | BPI and CD14. 
(a) The crystal structure of 
BPI shares 48% sequence 
homology with LBP and has two 
phospholipid binding sites. 
(b) Crystal structure of CD14 
showing two LPS binding 
pockets.   
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another member of the lipid transfer family, shares 48% 
sequence homology with LBP and its structure has been 
elucidated(Figure 726).27 However, BPI does not transfer LPS 
to the TLR4-MD-2 complex, so functionally LBP has different 
capabilities than BPI. 
 Initially, CD14 was identified as a co-receptor that 
binds to LPS transported by LBP and in turn relocates bound 
LPS for presentation to the TLR4-MD-2 complex. Further 
investigations have demonstrated that CD14 also participates 
in activation by Gram-positive cell-wall components, such as 
peptidoglycan and lipoteichoic acid,28 and mediates macrophage 
apoptosis.29 Thus, CD14 functions as a PRR with broad ligand 
specificity by recognizing structural motifs of diverse 
microbial products.  
  CD14 exists in soluble (sCD14) or in anchored membrane 
(mCD14) form by a glycosylphosphatidylinositol tail.30  Cells 
that do not express CD14, such as dendritic cells, are still 
able to respond to LPS by interacting with sCD14. During acute 
infection, serum levels of sCD14 and LBP rise31 and anti-CD14 
antibody protects primates from lethal LPS-induced septic 
shock.32 Low concentrations of LBP intensify LPS response, 
whilst high concentrations inhibit LPS activity in vitro and 
in vivo.26 Furthermore, sCD14 can also inhibit LPS response 
by facilitating LPS efflux from mCD14 and transporting it to 
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serum lipoproteins.33 To sum, dual stimulatory and inhibitory 
mechanisms of LBP and sCD14 afford systemic anti-inflammatory 
effects, potentially hindering pathological systemic 
responses.34 At the same time, LBP and sCD14 mechanisms can 
promote pro-inflammatory effects at local sites of infection, 
where they are needed.25   
   
2. TLR4-MD-2 Complex   
 The transmembrane TLRs were first discovered in 
Drosophila.35 In humans, a family of 10 genes encodes TLR1-
10, which are expressed by cells of the innate immune system. 
The 10 human TLR genes encode distinctive TLR polypeptides. 
Some TLRs are heterodimers of two polypeptides; others, such 
as TLR4, are homodimers (Table 224). TLRs contain a variable 
extracellular domain for detection of PAMPs from an array of 
pathogens, including bacteria, viruses and fungi.36 Toll 
Interleukin-1 Receptor (TIR) is the conserved cytoplasmic 
domain that conveys signal transduction intracellularly. TIR 
is critical for mediating protein-protein interactions 
between TLRs and five signal transduction adapter proteins, 
namely: myeloid differentiation primary response gene 88 
(MyD88), TIR domain-containing adapter inducing IFN-β (TRIF), 
TRIF-related adapter molecule (TRAM), TIR domain-containing 
adapter protein (TIRAP), and sterile α and HEAT-Armadillo 
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motif-containing protein (SARM).30 Different combinations of 
adapter proteins are utilized by distinct TLRs, which in turn 
determines downstream signaling events. The signaling 
pathways of TLRs are well defined, however the precise 
mechanisms by which TLRs are activated upon ligand-binding 
are not entirely understood.  Interestingly, TLR4 is the only 
recognized receptor that uses all five adapter proteins.30 
 The pathogen-recognition domains of TLRs consist of 
hydrophobic leucine-rich repeat (LRR) regions, which are 
Table 224 | Human TLRs recognize microbial ligands with 
pathogen associated molecular patterns (PAMPs).  
TLRs are encoded by 10 genes in humans from multiple chromosomes. 
TLRs acquired their nomenclature from the analogous receptor “Toll” 
found in the fruit fly Drosophila melanogaster. Differing PAMPs are 
found on distinct TLRs to confer variable ligand recognition. Some 
TLRs are heterodimers of two polypeptides and some exist solely as 
homodimers, such as TLR4.    
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responsible for receptor dimerization and the characteristic 
horseshoe-like shape (Figure 837). Variation in the 
composition and number of LRRs affords TLRs specificities for 
different microbial ligands.37 LRR family proteins are 
classified into 7 subfamilies, which are characterized by 
conformations. Most LRR proteins contain uniform radii and β-
sheet angles. However, the structure of some TLRs, including 
TLR4, substantially deviate from the consensus LRR 
confirmations. They are divided by structural transitions 
into three subdomains: N-terminal, central, and C-terminal 
(Figure 837).37 Irregular LRR sequences in the central domain 
cause the structural deviations from other LRR family 
proteins. Furthermore, the subdomain boundaries of TLRs play 
Figure 837 | Crystal structure 
of TLR4-MD-2 bound to LPS. 
(a) Top view of LPS bound to TLR4-
MD-2 complex. The primary 
interface is formed prior to LPS 
binding and the dimerization 
interface is created after LPS 
binding. (b) Side view of receptor 
complex. Lipid A is colored red and 
inner core region of LPS is colored 
pink. TLR4 is divided into N- 
central and C-terminal domains. 
LRRNT and LRRCT, leucine-rich 
repeat regions N- C-terminus 
respectively.    
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key roles in ligand binding, demonstrated by the primary 
contact interface of the TLR4-MD-2 complex.37 The N-terminal 
and central domains of TLR4 provide charge complementary for 
binding MD-2, forming a stable 1:1 heterodimer via two 
distinct regions, the A and B patches respectively.37 Notably, 
the TLR4-MD-2 complex is formed prior to binding LPS.  
 MD-2 is a soluble protein and can directly form a complex 
with LPS, yet LPS-MD-2 binding is enhanced with TLR4 
association. Importantly, there is no evidence to suggest 
that TLR4 can independently bind LPS, emphasizing the 
significance of LPS recognition by MD-2. MD-2 has a β-cup 
fold structure formed by two anti-parallel β-sheets.37 The β-
sheets are separated from one another, which in turn exposes 
the hydrophobic interior for ligand binding. This generates 
a large internal pocket that is ideal for binding flat 
hydrophobic ligands, such as lipid A. In fact, the interaction 
between LPS and the TLR4-MD-2 complex occurs with high 
affinity, and the KD is estimated to be 3-10 nM.38  
 
3. Signal Transduction Pathway & Mediators 
 As a homodimer, TLR4 binds MD-2 to form two 1:1 
complexes. Then, sCD14 or mCD14 present LPS to the TLR4-MD-2 
complex, which in turn propagates the signal by dimerization 
of the entire receptor complex. Such extracellular 
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recognition of LPS causes the cytoplasmic TIR domain of TLR4 
to bind to a similar TIR domain of MyD88 (Figure 924). Once 
TIR is bound to MyD88, a separate domain of MyD88 binds to 
the protein kinase IRAK4, whereupon in auto-phosphorylates 
itself and dissociates from the complex (Figure 924). IRAK4 
propagates the signal by phosphorylating the adapter protein 
Figure 924 | MyD88-dependent pathway induces NFκB to 
initiate transcription of cytokines upon LPS recognition 
by TLR4-MD-2 complex. 
Pathway from left to right: (1) LPS is detected by the TLR4-MD-2 
complex. (2) Receptor complex dimerization causes cytoplasmic TIR 
domain to bind MyD88. (3) MyD88-associated IRAK4 auto-phosphorylates 
causing dissociation from MyD88. (4) Unbound IRAK4 phosphorylates 
TRAF6, which in turn induces a kinase cascade leading to activation 
of IKK. (5) Activated IKK phosphorylates IκB, leading to its 
degradation and subsequent release of transcription factor NFκB. 
(6) NFκB translocates into nucleus to initiate transcription of 
cytokine genes. (7) Cytokine mRNA is translated at ribosome and 
secreted extracellularly by the ER. Abbreviations: TIR, toll 
interleukin-1 receptor; IRAK4, interleukin-1 receptor-associated 
kinase 4; TRAF6, TNF receptor associated factor 6; IKK, inhibitor 
of κB kinase; IκB, inhibitor of κB; ER, endoplasmic reticulum.             
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TRAF6, which induces a cascade of events, eventually leading 
to activation of the kinase complex IKK (inhibitor of κB 
Kinase). IKK performs the critical function of activating a 
transcription factor termed nuclear factor κB (NFκB), which 
conducts significant operations to both innate and adaptive 
immune responses.39  NFκB is held in an inactive state in a 
cytosolic complex with inhibitor of κB (IκB). When IKK 
phosphorylates IκB, it releases NFκB from inhibition. 
Consequently, NFκB travels to the nucleus where it induces 
the transcription of genes for cytokines and numerous other 
proteins required to amplify the inflammatory response.39  
 
4. TRIF-dependent 
 Alternatively, an MyD88-independent signaling pathway 
can be triggered by the recruitment of TRIF and TRAM.30 These 
adapter molecules play a key role in activating interferon 
regulatory factor IRF3, which is essential for the expression 
of type I interferons, like IFN-β.30 Also, exuberant nitric 
oxide (NO) production results by activating the MyD88-
independent (TRIF-dependent) pathway.40 NO performs a major 
role in inflammatory pathogenesis as a signaling molecule and 
is thought to induce vasodilation.40 To add, NFκB can be 
activated by the TRIF-dependent pathway, but in a later-
phase. It is speculated that subcellular localization of TLR4 
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distinguishes the activation of the two signaling pathways. 
For instance, recognition of LPS at the plasma membrane 
activates the MyD88-dependent pathway, but in contrast, 
recognition of LPS at the endosome initiates the TRIF-
dependent pathway. Nonetheless, induction of either IRF3 or 
NFκB activates the transcription of genes, which for the anti-
viral response are type I IFNs and in the pro-inflammatory 
response, TNFα.      
 
5. TNFα 
 NFκB induces the transcription of TNFα and other pro-
inflammatory cytokines including: IL-1β, IL-6, IL-8, IL-12 
and IL-23.41 Of these, TNFα is one of the most important 
soluble mediators of inflammation. It is responsible for an 
array of signaling events and is mostly generated from 
activated macrophages/monocytes.42 TNFα is produced rapidly 
and can be detected within 15 minuets of LPS exposure in cell 
culture and in vivo peaks at 1.5 hours.43 TNFα causes 
contrasting effects to endothelial cells of blood vessels in 
the infected tissues.44 In a systemic infection, macrophages 
in the liver and spleen secrete TNFα into the bloodstream for 
systemic circulation. The result is decreased blood flow from 
vasodilation and diffuse leakage of plasma. TNFα released 
into the bloodstream also causes the liver to secrete acute-
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phase proteins, which include Mannan-binding lectin and C-
reactive protein. Both are critical to complement pathways 
and exacerbate the inflammatory response. 
 
6. The Coagulation Cascade 
 In localized infections, TNFα secretion causes blood 
flow to increase and endothelia to produce platelet-
activating factor, which clots blood and blocks nearby 
vessels.45 This induction of the coagulation cascade obstructs 
pathogens from entering the bloodstream, thereby preventing 
their spread. However, this process can impede delivery of 
oxygen to the tissues and can induce further inflammatory 
injury indirectly through the response to hypoxemia.  
Usually, induction of the coagulation pathway induces 
anticoagulant mechanisms to limit its progression. However, 
when the infection is diffuse, as in sepsis, an imbalance of 
the procoagulant and anticoagulant systems develop, 
generating a sustained hypercoagulable state.46 Systemic 
widespread clotting depletes coagulation proteins and 
platelets from the blood. This process can lead to a bleeding 
complication syndrome called DIC. Clinically, DIC is 
increasingly common as a patient progresses from severe 
sepsis to septic shock.46 Simultaneously, microvascular 
thrombosis develops contributing to end-organ damage.46 
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Without intervention, lack of blood flow to the organs causes 
multiple organ failure, which ultimately determines the 
septic patients prognosis. 
 Overall, multiple and diverse pathways lead to a hyper-
activated immunological response that manifests end-organ 
damage in sepsis. LPS itself is nontoxic but its adverse 
effects emanate through systemic activation of host-derived 
inflammatory mediators. Attempting to block a single 
cytokine, like TNFα, would be inadequate due to the large 
quantity and diversity of cytokines produced by activated 
cells. Consequently, the path towards generating enhanced 
therapeutics for the septicemic patient does not lie with 
interrupting downstream incidents, but by blocking the 
initial signaling events of the cascading inflammatory 
response.  
 
C. Lipid A Analogues 
 Synthesis of lipid A analogues first emerged with the 
ambition to understand the chemical structures that were 
principally responsible for endotoxic activity in sepsis.47 
Some of the most informative studies of structure-activity 
relationships of lipid A have utilized synthetic and natural 
antagonist.48 In particular, the use of a naturally occurring 
precursor from the constitutive biosynthesis pathway in E. 
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coli called lipid IVa (2) and a nonpathogenic lipid A molecule 
from Rhodopseudomonas sphaeroides. The latter of which served 
as the structural basis for the drug candidate Eritoran (3). 
In phase III clinical trials, Eritoran (3) did not perform 
better than existing treatments for sepsis.49 However, it did 
demonstrate efficacy in combating cytokine storm induced from 
strains of influenza in animal models.50 Another key 
contributor to our continued understanding was isolation and 
characterization of 3-O-desacyl-4’-monophosphoryl lipid A  
(MPL)(4).51 Comparison of MPL derivatives provides clues for 
Figure 10 | Structure of E. coli lipid A and derivatives. 
(1) Structure of agonistic E. coli lipid A. (2-5) Antagonist to 
LPS signaling at TLR4-MD-2 complex.    
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chemical alterations that direct endotoxicity and 
adjuvanticity. Development of the less endotoxic MPL has led 
to its widespread use as a component of numerous licensed 
vaccines, including HBV and papilloma, and has been proven 
both safe and effective.51 Detoxification was achieved by acid 
hydrolysis of the 1-O-phosphono group followed by base 
hydrolysis of the 3-hydroxytetradecanoly group to yield MPL 
(4). In addition, studies revealed that lipid IVa (2) has 
conflicting properties between human and murine cells.51 It 
was shown to inhibit the induction of inflammatory cytokines 
in human cells co-treated with LPS or lipid A. However, in 
murine cell lines lipid IVa (2) was shown to be a potent 
inducer of inflammatory cytokines. These species-specific 
results were later explained by structural differences 
between human and murine TLR4-MD-2 complexes. Specifically, 
lipid IVa (2) caused contrasting effects on dimerization of 
the TLR4-MD-2 receptor complex, which is required for 
activation of downstream signaling. Expectedly, lipid IVa (2) 
was shown to promote receptor dimerization in murine, but not 
human TLR4-MD-2 complexes.  
 Activation of the TLR4-MD-2 complex can lead to distinct 
signaling pathways namely; the MyD88-dependent or the TRIF-
dependent pathways. Induction of the MyD88-dependent pathway 
causes production of proinflammatory cytokines such as TNFα, 
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whilst TRIF-dependent pathway activation leads to NO and IFN-
β production. Teasing apart the structural determinants of 
lipid A that induces the former or the latter has implications 
in determining subsequent endotoxicity or adjuvanticity.51 
Previously stated, CD14 is a PRR that directly binds to LPS 
and chaperones the formation of the dimerized TLR4-MD-2 
complex. At low concentrations of LPS, CD14 plays an increased 
role in formation and subsequent receptor dimerization 
leading to induction of the MyD88-dependent pathway. Albeit, 
CD14 is not essential for this induction when LPS is in higher 
concentrations. CD14 is also required for TLR4 endocytosis 
and internalization of the entire receptor complex into the 
endosome, thereby inducing the TRIF-dependent pathway.51 It 
has been demonstrated that TLR4 antagonist, such as lipid IVa 
(2) and Eritoran (3), strongly interact with CD14, thereby 
inhibiting re-localization of the receptor complex.52 
 
1. Monosaccharide Mimetics 
 Researchers have attempted to separate beneficial 
immunopharmacological attributes from adverse 
pathophysiological endotoxic properties of lipid A by 
performing structure-activity analyses of simplified 
structures. Lipid A has a basic endotoxic structure of an 
amphipathic molecule, with distinct hydrophilic and 
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hydrophobic domains. The association of a polar backbone 
supporting an apolar region is vital for its antagonistic or 
agonistic properties. However, the specific structure of the 
glucosamine disaccharide backbone is seemingly not stringent 
in directing which biological activity will result. Synthetic 
lipid A derivatives with one of the glucosamine disaccharide 
residues replaced with acyclic or pseudo-peptides have 
contained similar activities of E. coli lipid A, whilst others 
have demonstrated antagonistic properties.53 Interestingly, 
both or at least one phosphate, or bioisotere of, substituents 
at the anomeric or 4’-carbons seem to be a prerequisite for 
substantial biological activity. 
 The approach of dividing lipid A into reducing and non-
reducing halves has been utilized to develop therapeutics. 
Lipid X (5) is a biosynthetic precursor of lipid A with a 
structure that corresponds to the reducing monosaccharide 
half, which consist of 1-phosphoryl, diacyl 2-N-, 3-O-, 
hydroxytetradecanoyl-D-glucosamine .52 Synthesized structures 
that emulate Lipid X (5) have shown to lack both endotoxic 
and immunostimulatory properties. To add, Lipid X (5) 
derivatives were often antagonist of lipid A or LPS.52 In 
comparison, divided lipid A analogues of the non-reducing 
half also produce attenuated endotoxic activities. For 
example, GLA-60 (6) is a lipid A analogue of the non-reducing 
	 36	
section and displays a 4-phosphoryl D-glucosamine 
monosaccharide moiety with three acyl chains of 12-14 carbons 
in length. Interestingly, GLA-60 (6) based compounds are 
relatively potent adjuvants, provide non-specific protection 
from bacterial and viral infections and are tumor 
regressive.54 Furthermore, current studies have revealed 
monosaccharide lipid A analogues as potential adjuvants for 
cancer treatments with multiple phase 1 trials underway.55–65 
 
2. Antagonizing LPS-Induced Dimerization  
 Despite substantial data on the activity of both 
isolated and synthetic lipid A derivatives, there 
unfortunately is no universal correlation between the 
chemical structure of lipid A and its activity in the TLR4-
MD-2 complex. However, elucidation of the crystal structure 
of the TLR4-MD-2 complex bound to antagonistic lipid IVa (2) 
or Eritoran (3) and agonistic E. coli lipid A (1) has 
contributed a better understanding of structural requirements 
for the receptor complex (Figure 1137).37  
 Previously stated, TLR4 as a homodimer binds MD-2 to 
form two 1:1 complexes that then dimerize upon ligand binding. 
LPS binding induces dimerization by creating an additional 
binding interface between TLR4 and MD-2. To distinguish the 
secondary dimerized heterotetrameric TLR4-MD-2* complex from 
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primary TLR4-MD-2, an asterisk is utilized. Accordingly, the 
carbon chains of lipid A interact with the hydrophobic pocket 
of MD-2. Five of the six lipid chains of agonistic LPS are 
enclosed by the hydrophobic pocket and the sixth is uncovered 
to the surface of MD-2 (Figure 1237), whilst all four lipid 
chains of lipid IVa (2) are buried (Figure 1137).37 The sixth 
lipid chain of LPS forms a hydrophobic interaction with 
Figure 1137 | LPS antagonist shift the anomeric phosphate. 
The size of the MD-2 pocket is unchanged after binding agonistic or 
antagonistic lipid A. Added space for lipid binding displaces the 
anomeric phosphate upwards ~5Å, allowing interaction with nearby 
positive charges on TLR4 and TLR4*. (a) Comparison of LPS and 
Eritoran binding. (b) Comparison of LPS and lipid IVa binding.   
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phenylalanine residues of TLR4*. This provides an explanation 
why previous studies have shown that six lipid chains are 
optimal for activation of TLR4 signal transduction when 
compared to derivatives with fewer lipid chains.21 The ester 
and amide groups that connect the lipophilic chains to the 
polar head group of lipid A are also exposed to MD-2 in 
binding agonist E. coli lipid A (1). However, these 
interactions generate a minimal number of weak bonds with 
TLR4* and TLR4.37 This is supported by biological activity of 
lipid A analogues, whereupon more robust ethers have been 
Figure 1237 | Dimerization of receptor complex with LPS. 
Lipophilic chains interact with the hydrophobic pocket of MD-2. 
The exposed R2 chain interacts with TLR4* at dimerized interface. 
The MD-2 pocket is depicted with the mesh. Primary and secondary 
dimerized interface are depicted TLR4 and TLR4 and TLR4*, 
respectively.      
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substituted.21 The two phosphate groups bind to residues of 
TLR4-MD-2 and at the dimerization interface of TLR4*, thus 
supporting the formation of a stable (TLR4-MD-2)2 dimerized 
complex. Both the 1-phosphate and 4’-phosphate of lipid A 
bind to positives patches on TLR4 and TLR4* (Figure 1337). The 
significance of these two interactions has been established.  
As demonstrated with MPL (4), removal of one phosphate group 
greatly reduces the endotoxicity of LPS. Secondly, when the 
positively charged patch of TLR4* was mutated to an alanine 
residue, NFκB and IFN-β activity was abolished.66 This finding 
Figure 1337 | Both phosphates of LPS lipid A interact at 
dimerized receptor complex. 
The 1-phosphate and 4’-phosphate conduct dimerization by binding 
positively charged arginine and lysine residues of TLR4 and 
TLR4*. These two ionic interactions are critical elements for 
activation of TLR4-MD-2 complex. Removal of one phosphate group 
greatly reduces endotoxicity.    
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suggest that the 1-phosphate of lipid A is essential for 
activation of both MyD88-dependent and TRIF-dependent 
pathways. Thus, subtle structural changes at the anomeric 
phosphate of lipid A could illuminate the path towards guided 
activation between endotoxicity and adjuvanticity.  
 
D. Phosphonates   
 The phosphate group [(HO)2P(=O)OR] is a fundamental 
component of all living systems. It is essential for molecular 
replication, cell biochemistry, signaling pathways, and 
regulation of metabolic processes.67 Phosphonate analogs of 
phosphates, wherein the phosphate ester bond has been 
replaced with the hydrolytically stable phosphonate  
[(HO)2P(O)R (R=carbon residue)], often contain enticing 
physiological properties (Scheme 1).68–72 An alpha substituent 
(X) can be used to return the pKa of the phosphonic acid to 
the values typical of the corresponding phosphate ester. In 
addition, the tetracordinate phosphoryl group is well 
recognized as an excellent mimic for the tetrahedral 
transition state of ester and amide hydrolysis.73 More 
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surprisingly, phosphonic acids can successfully act as non-
isosteric replacements for carboxylic acids.74 
	
1. Phosphono-sugar Analogues  
 Phosphonates have become increasingly useful in the 
development of tools for biological investigation and the 
formulation of novel compounds for medicinal chemistry. For 
instance, phosphonate derivatives that contain additional 
functionality in the carbon chain are extremely versatile by 
exhibiting activities as receptor agonists-antagonists75 and 
herbicidal, antibacterial, and antiviral agents76–80, usually 
through the inhibition of specific enzymes.81,82  
 There are many examples of phosphono-sugars where the 
phosphonate is located on a ring substituent. Such compounds 
are important in the development of non-hydrolysable 
phosphonate mimics of bioactive carbohydrate phosphates, such 
as nucleotides.83–85 Research in this area has resulted in 
several examples of biologically relevant molecules. 
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III. Results & Discussion 
 
1. Development of Lipid X Mimetics  
 Structural properties of the TLR4 
receptor complex provide insight into LPS 
binding and subsequent dimerization for 
potentiating biological responses. 
Numerous lipid A variants have been 
synthesized to date and demonstrate that 
subtle changes in the length of the 
lipophilic chains, degree of 
phosphorylation of the polar backbone and 
modification of the disaccharide moiety 
can profoundly alter biological activity.48 The monosaccharide 
Lipid X (5) has been shown to block priming of TLR4-dependent 
neutrophils and antagonizes LPS signaling.52 Furthermore, 
previous studies suggest that dual targeting of MD-2 and CD14 
is accomplished with Lipid X (5) based analogues.52 A 
successful approach to downregulating LPS signaling would 
involve compounds that compete with LPS binding to MD-2 and 
CD14, consequently inhibiting inflammatory signal 
transduction pathways by impairing LPS-initiated receptor 
dimerization and internalization. Due to its anti-endotoxic 
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activity, coupled with a simplified monosaccharide moiety 
that would prove more cost effective and more readily 
scalable, we selected Lipid X (5) based derivatives to 
synthesize.  
 Monosaccharide based TLR4 receptor targeting could also 
afford compounds with enhanced water solubility. Previously 
synthesized lipid A mimetics suffer from poor solubility in 
aqueous media86, which is essential for improved 
bioavailability and a more favorable pharmacokinetic profile. 
Significantly, gaining structural insight to guide future 
explorations in distinguishing endotoxicity and adjuvanticity 
are paramount to progress lipid A 
analogues. To date, C-glycosylated 
phosphono-glucoside mimetics of Lipid X 
have not been explored. Thus, we employed 
traditional carbohydrate chemistry 
techniques to develop a non-hydrolysable 
phosphonate mimic of Lipid X (12α) and 
assessed its biological activity for 
antagonizing LPS in vitro.  
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2. Overall Synthesis  
  
 Synthesizing TLR4-MD-2 receptor antagonists by 
incorporating a phosphonate onto a ring substituent will 
generate the non-hydrolysable Lipid X mimetic (Scheme 2). The 
proposed synthesis begins with the formation of 
peracytylated-thio-β-D glucoside (7) from penta-acylated 
Scheme 2 | Reagents and Conditions (R = C14H29) 
(i) PhSh, BF3.Et2O, DCM, rt, 4h, (78%); (ii) 1. NaOMe, MeOH/DCM 
1:10, 0 ºC, 1h, (99%); 2. PhCH(OMe), pTsOH, DMF, 60 ºC, 4h, (80%); 
(iii) NaH, tetra-N-butylammonium iodide, Bromo-tetradecane, 
DMF/THF 2:3, 40ºC, 24h, (78%); (iv) 1. N-IS, 1.1 eq. TFA, DCM, rt, 
1h; 2. Piperidene, rt, (84-94%); (v) THF, NaH, ((MeO)2(O)P)2CH2, rt, 
2-24h, (48-54%); (vi) 15% TFA in wet DCM, rt, 1h, (77%); (vii) THF, 
NaCNBH3, 2 N HCl/Et2O, rt, 30 min., (84%).  
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glucose (6) as depicted,87 deacetylation of the peracytylated-
thio-β-D-glucoside (7) will generate the tetrol, which will 
then be protected as a benzylidene. The resulting diol (8) is 
alkylated creating both lipophilic chains (9). Hydrolysis of 
the thiophenol forms the anomeric hydroxy (10) that is 
subjected to Horner–Wadsworth–Emmons reaction conditions to 
introduce the phosphonate moiety (11). Hydrogenolysis or 
selective C-4 ring cleavage of the benzylidene protecting 
group will afford novel phosphono-sugar (12) and (13) 
analogues of lipid X. The proposed route also allows for 
divergent chemistry to produce a library of compounds (Scheme 
3) to more fully explore structure activity relationships of 
Lipid X.   
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3. Protecting Group Strategy 
 Strategical implementation of protecting groups is an 
important component for any total synthesis of organic 
molecules, but this is especially true in carbohydrate 
chemistry. Carbohydrates present a large number of poly-
functionalized groups. Most of them are of the same sort, 
that is in the form of free hydroxyls. Success depends upon 
differentiating the relative reactivity of the hydroxyls, 
which are reflected by electronic and conformational factors. 
The different reactivity of the hydroxyls manifest from 
namely: one primary (C-6), several secondary (C-2,-3, & -4), 
and an acetalic group at the anomeric center. The most 
reactive is the hydroxyl at the anomeric carbon followed by 
the primary alcohol at C-6. The secondary hydroxyls contain 
varying reactivity due to their equatorial or axial 
orientations. This feature of carbohydrates necessitates 
regioselective strategies, which can be arduous at times. 
  Protecting groups also impart other effects of the 
compound. They can alter the reactivity of a molecule and can 
also participate in the reaction itself, therefore affecting 
the stereochemical outcomes. Ideally, it should be possible 
to introduce and remove more permanent protecting groups with 
regiocontrol and high efficiency. They should be stable under 
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conditions used for the addition and removal of temporary 
protecting groups. Acetals confer this stability and in 
addition contain efficient introduction and deprotection 
properties, for instance simultaneous protection of C-4 and 
C-6 hydroxyls.  Of the acetals, we employed benzaldehyde 
dimethyl acetal PhCH(OMe)2 under standard acetalization 
conditions with pTsOH as the acid catalyst to produce 
compounds (9) and (18) in good yields.  
 An added advantage of the benzylidene acetal as a 
protecting group is the number of subsequent modifications 
that can yield various protecting group patterns (Scheme 4). 
Selective reduction to yield benzyl ethers and free hydroxyl 
groups are readily utilized with a hydride reagent in 
combination with a Lewis acid. Combination of LiAlH4/AlCl3 
would afford 4-O-benzyl derivatives unveiling the primary 
Scheme 4 | Examples of reductive cleavage 
of benzylidene acetals.  
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alcohol at C-6, whilst NaCNBH3/HCl will give the opposite 6-
O-benzyl ether, as we demonstrated in formulating compounds 
13α, 13β, 15, 20 and 23.   
 Also, complete cleavage of benzylidene acetals can be 
achieved under mild conditions with 15% TFA in wet DCM or 
with Pd catalyzed H2 reduction. For ease of use, we utilized 
15% TFA in DCM for complete benzylidene cleavage to produce 
4,6-diol compounds 12α, 12β, 14 and 22 in good yields. Not 
presented in this embodiment of work, but a useful synthetic 
tool is employing benzylidene acetals under oxidative 
conditions, usually NBS in CCl4, to yield benzoyl ester 
protected halogen derivatives. 
 
4. Anomeric hemiacetal protection 
 Thioglycosides are readily prepared by nucleophilic 
substitution at the anomeric center, commonly from anomeric 
acetates by reaction with thiols in the presence of a Lewis 
acid, such as BF3.Et2O (Scheme 5). Thioglycosides exhibit 
remarkable stability and withstand diverse chemical 
modifications, leaving the thioglycoside functionality 
intact. Most carbohydrate protecting group manipulations, 
including benzylidene introduction and selective cleavage, 
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can be performed. In addition, thioglycosides can serve as 
glycosyl acceptors to construct oligosaccharides.  
 Thus, we protected the anomeric carbon of (6) with 
thiophenol to produce (7) prior to 4,6-O-benzylidene (8) 
formation. However, in a subsequent step for our synthesis, 
thiphenol proved its stability. To generate the phosphono-
sugar, the anomeric thio-protecting group needs to first be 
hydrolyzed. We found this step to be difficult using commonly 
applied methods. We observed the conventional strategies 
using N-bromo- and N-iodo-succinimide, and N-iodosaccharin in 
the presence of minute amounts of H2O to be unsuccessful. We 
also tried catalytic auric chloride as a strategy to activate 
thioglycoside donors, which had recently been reported. 
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Scheme 5 | Thioglycoside Anomeric Protection.  
R = Ph or Et 
(i) Mechanism of to generate thioglycosides from penta-acylated-β-
D-glucose, depicting the formation of the α or β anomers. We utilized 
BF3.Et2O in the presence of ethanethiol and thiophenol. Thiophenol 
was found to be β-selective, whilst ethanethiol generated a mixture 
of anomers.     
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Unfortunately, this method also proved unsuccessful. The 
over-arching problem observed in these reactions were with 
solubility. Addition of tiny amounts of H2O, required for 
hydrolysis in these reaction methods, resulted in the 
starting thioglucoside (9) to rapidly precipitate from 
solution in a variety of solvents (DCM, Et2O, THF, dioxane, 
acetone and others). This issue lead us to generate the more 
polar anomeric protection of ethanethiol (18). In comparison, 
ethanethiol derivatives produced higher yields in each 
reaction step previous to anomeric hydrolysis (Scheme 6). 
Ethanethiol derivatives were found to be more soluble 
compared to thiophenol compounds at the anomeric hydrolysis 
step. However, yields were low using NBS and 2,6-lutidiene in 
dioxane and the starting material (18) still demonstrated 
some solubility issues.  
Scheme 6 | Reagents and Conditions (R = C14H29) 
(i) EtSh, BF3.Et2O, DCM, rt, 6h, (83% as α/β mixture); (ii) 1. NaOMe, 
MeOH/DCM 1:10, 0 ºC, 1h, (99%); 2. PhCH(OMe), pTsOH, DMF, 60 ºC, 
4h, (88%); (iii) NaH, tetra-N-butylammonium iodide, Bromo-
tetradecane, DMF/THF 2:3, 40ºC, 24h, (83%); (iv) 1. N-IS, 15% TFA 
in DCM, rt, 1h; 2. Piperidene, rt, (84-94%); (v) THF, NaH, 
((MeO)2(O)P)2CH2, rt, 2-24h, (48-54%); (vi) NBS, 2,6-lutidene, 
dioxane, rt, 6h, (53%). Note: α-anomer was seperated and utilized 
for (ii).  
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 Eventually, we did develop a method to alleviate the 
solubility issues encountered by the particularly hydrophobic 
compounds (9) and (18). To complete this step in the 
synthesis, the thioacetal (9) was hydrolyzed by treatment 
with NIS and dry TFA in DCM, followed by addition of 
piperidine to cleave the intermediate triflouroacetate and 
afford the hemiacetal (10) as a 1:1 anomeric mixture in high 
yield (~90%). This step permitted hydrolysis without the use 
of H2O, which evoked our problems with solubility. 
 
5. Synthesis of lactone derivatives 
 Lipid A from the LPS of the nitrogen fixing bacterial 
species Rhizobium sin-1 (24) is structurally distinct, in 
comparison to endotoxic E. coli lipid A. It is completely 
devoid of phosphates, has a very long chain fatty acid (27-
hydroxyoctacosonic acid), and contains a D-gluconolactone 
moiety at the reducing end (Scheme 8). Interestingly, 
compound (24) and a synthetic disaccharide derivative (25) 
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Scheme 7 | Deprotection of Thioglycoside. 
Reagents and Conditions: 1. N-IS, 1.1 eq. TFA, DCM, rt, 
1h; 2. Piperidene, rt, (84-94%)   
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have shown to be potent in antagonizing LPS-induced cytokine 
production in human macrophage cells by inhibiting both TRIF- 
and MyD88-dependent pathways.21 Intriguingly, monosaccharide 
lipid A derivatives containing a D-gluconolactone moiety have 
not been investigated. Thus, we decided to also synthesize 
Lipid X derivatives devoid of a phosphonate, yet containing 
the D-gluconolactone moiety (21, 22, and 23).  
    
 Oxidation of carbohydrates is a widely-utilized 
technique to attain derivatives with profoundly modified 
reactivity and character. Mono-oxidation of carbohydrates at 
the anomeric center produces aldonolactones with reactivity 
unlike that of the corresponding aldoses. 
Scheme 8 | Rhizobium sin-1 lipid A.  
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 A facile synthetic technique we used to produce the 
desired Lipid X D-gluconolactone derivative (21) was by 
performing a Ley-Griffith oxidation to compound (10). This 
technique utilizes the ruthenium based oxidant 
tetrapropylammonium perruthenate N(C3H7)4RuO4 (TPAP) with 1.5 
equivalents of co-oxidant N-methylmorpholine N-oxide (NMO) in 
DCM as shown in Scheme 9. TPAP operates catalytically at room 
temperature and is devoid of explosive side products. When 
TPAP is used in the presence of NMO (Scheme 10), high yields 
are usually observed and this was supported in the formation 
of our D-gluconolactone derivative (21).  
  
Scheme 9 | Ley-Griffith oxidation mechanism.  
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6. Chemistry of Horner-Emmons Reaction 
 This reaction makes use of phosphonate anions as the 
nucleophilic species.  This methodology is applicable to the 
formation of C-glycosides (11) from sugars (Scheme 11). 
However, considering the intermediate α, β-unsaturated ester 
and the acidity of the proton at C-2, epimerization of the 
stereocenter is possible. Indeed, the reaction conditions 
that generated (11) did produce four diastereomers that were 
Scheme 11 | Generated phosphono-sugar mimetics 
R = C14 
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Scheme 10 | Anomeric oxidation produces D-glucono-δ-lactone.  
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isolated using preparatory reverse-phase HPLC. The byproducts 
with the “manno” configuration are not of biological 
significance, therefore were not subject to further chemistry 
for investigation. The anomeric ratio (α:β) varied from 3:2 
to 1:1.  
 We unsuccessfully employed multiple strategies using 
traditional carbohydrate synthetic techniques to circumvent 
the generation of four diastereomers and to elicit 
regioselectivity in introduction of the phosphonate to C-1. 
A traditional approach to the methylene phosphonate analog 
(Scheme 12) involves reacting the benzylidene protected 
compound (10) with tetramethyl methylenediphosphonate (10b) 
to yield the vinyl phosphonate (10a) followed by base 
catalyzed cyclization to yield the phosphonate derivatives 
(11-α/β). In addition, the same mechanism that elicited 
epimerization at C-2 could account for the formation of the 
side product we isolated (11c) (460 mg, 29.2%), as depicted 
in Scheme 13. The elimination or reprotonation at C-2 produced 
Scheme 12 | Synthesis of phosphono-sugar mimetics 
R = C14 
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(11c) and contributed to the overall low yield (50.4%) of 
this reaction that generated four diastereomers of (11).  
 
  
 We applied the use of several bases including anhydrous 
Ba(OH)2 in THF, KHMDS at -78ºC in THF, DBU in THF, DIPEA in 
THF, and Cs2CO3 in dry i-PrOH. Much to our surprise and without 
explanation, none of these bases generated the desired 
phosphonate product (11-α/β), except for NaH in THF. 
Crystallization of the 4,6-O-benzylidene β-glucoside (11β) 
was achieved, but not the α-configuration. Figure 14 is the 
depiction of the x-ray structure of (11β).  
Scheme 13 | Generation of side product 11c. 
R = C14 
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  At the reducing end of the sugar, the aldehyde is masked 
in form of a hemiacetal. However, the equilibrium between the 
hemiacetal and ring-opened form, especially considering ring 
strain of the 4,6-O-benzylidene, is highly favored towards 
the hemiacetal. Even so, the Wittig reaction can drive the 
equilibrium entirely to the ring-opened form, producing the 
newly formed olefin that can also be cyclized with addition 
of a base. To this end, we attempted to utilize a Wittig 
reagent that is readily available from Sigma Aldrich, 
diphenyl(triphenylphosphoranylidenemethyl)phosphonate 
Ph3P=CHPO(OBn)2, to introduce a phosphonate to (10) with 
improved regioselectivity. This technique has been 
demonstrated to produce C-glycosylated phosphonate analogues 
with regioselectivity of the α-anomer. Moreover, the anomeric 
Figure 14 | X-ray structure of 11. 
Only 4,6-O-benzylidene β-glucoside could be crystalized for 
x-ray crystallography.   
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ratio of the product mixture is dependent upon the time 
exposure to the base. The Wittig method has been proven 
valuable for the formation of olefins from aldehydes and 
ketones using phosphorus ylides. Unfortunately, this method 
too did not work on our compound (10).   
 
7. Biological Activity Assay  
 Compounds (11α, 11β, 12α, 12β, 13α, 13β, & 22) were 
selected to be evaluated for anti-inflammatory potential 
against LPS-induced human acute monocytic leukemia (THP-1) 
cells. THP-1 cells provide an ideal system for studying 
inflammatory processes.88 They serve as a model for peripheral 
monocytes/macrophages and their responsiveness to bacterial 
infection.88 Unfortunately, benzylidene protected phosphono-
sugar mimetics 11α and 11β were not soluble in DMSO, therefore 
were not suitable for cell culture studies. The same result 
of insolubility was also observed for selectively ring-opened 
6-O-benzyl ether compounds 13α and 13β.  Albeit, they were 
seemingly more soluble than the completely protected 
benzylidene derivatives, more than likely due to the unveiled 
hydroxy at C-4. However, both complete benzylidene cleaved 
phosphono-mimetics 12α and 12β and lactone derivative 22 were 
readily soluble in DMSO. Due to time constraints, we selected 
to evaluate the targeted and more biologically relevant α-
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anomer 12α and lactone derivative 22 by preincubating THP-1 
cells with the compounds prior to cell stimulation with of E. 
coli LPS as outlined in experimentals. Modulation of TNFα 
production was analyzed in vitro and measured by ELISA.  
 
8. Biological Activity             
 THP-1 cells were stimulated with LPS in the presence of 
increasing concentrations of compounds 12α (Figure 14, red) 
and 22 (Figure 15, red) to test antagonistic activity. THP-1 
cells were also treated with increasing concentrations of 
compounds 12α and 22 in the absence of LPS to examine 
agonistic activity (Figure 14 & 15, blue). Neither 
significantly demonstrated agonistic properties. The zero 
concentration of compound represents a control treatment of 
100 ng/mL LPS and the same percentage of DMSO included with 
the compounds.    
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 The targeted α-phosphonate 12α did not demonstrate 
antagonistic properties. However, compound 12α appears to 
elicit slight synergistic effects by increasing TNFα 
production at 100 µM. This finding may be attributed to cell 
toxicity. 
Figure 14 | Effects to TNFα production in THP-1 cells in	the	
presence	of	phosphono-sugar	12α. 
Compound 12α does not elicit antagonistic effects. THP-1 
cells were treated as described in experimentals. Y-axis 
shows TNFα concentration in pg/mL. X-axis displays 
increasing concentrations of 12α in the presence of LPS 
(red) and in absence of LPS (blue).      
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 In contrast, D-glucono-δ-lactone derivative 22 did 
demonstrate antagonism by reducing TNF	α production by 41% at 
the lowest tested concentration of 1 µM. At concentrations of 
3 µM and 10 µM TNFα production was further decreased by 52% 
and 64% respectively.  
Figure 15 | Effects to TNFα production in THP-1 cells in	the	
presence	of	D-glucono-δ-lactone derivative 22. 
Compound 22 displays antagonistic properties. THP-1 cells 
were treated as described in experimentals. Y-axis shows 
TNFα concentration in pg/mL. X-axis displays increasing 
concentrations of 22 in the presence of LPS (red) and in 
absence of LPS (blue).      
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IV. Conclusion & Future Directions 
 
 Sepsis is a clinical manifestation of a dysregulated and 
exaggerated inflammatory response to pathogenic microbes 
arising from our own innate immunity. Traditional 
interventions, which are geared towards attenuating the 
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Figure 16 | Compound 22 displays LPS antagonism. 
THP-1 cells were treated as described in experimentals. Y-
axis shows TNFα concentration in pg/mL. X-axis displays LPS 
without compound 22 (left) and going right are increasing 
concentrations of 22 in the presence of LPS. 41% inhibition 
is observed at 1 µM. Maximum inhibition of 64% was achieved 
at 10µM.    
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symptoms of sepsis, have proved insufficient. This is 
supported by rising annual healthcare expenditures and high 
mortality rates in diagnosed patients. Moreover, antibiotic 
resistant strains of bacteria are ever-growing and are a cause 
for concern. Spearheaded efforts to enhance therapeutics by 
disrupting underlying mechanisms of immunopathogenesis will 
lead to improved patient outcomes.  
 The lipid A component of LPS causes immunopathogenesis 
by initiating TLR4-MD-2 receptor dimerization, consequently 
inducing the inflammatory pathway. Compounds that out-compete 
LPS would disrupt TLR4-MD-2 signal transduction and 
downregulate LPS signaling. Previously synthesized lipid A 
analogues demonstrate that subtle structural changes 
critically impact biological activity. Elucidating key 
chemical structure-activity relationships between lipid A 
variants will guide future explorations. 
      Our lipid A analogues were based upon the 
monosaccharide Lipid X with the aim to produce TLR4-MD-2 
antagonist with more robust, simpler, and readily scalable 
chemical structures. Astute chemical modifications to 
substituents were aimed at improving bioavailability and 
solubility of lipid A analogues.  
 Synthesizing the C-glycosidic phosphono-sugar 12α 
produced a non-hydrolysable analogue that could circumvent 
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inactivation by host phosphatases. Unfortunately, 12α did not 
demonstrate LPS antagonism. Future attempts at synthesizing 
a phosphonate derivative should cleave the methyl protecting 
groups using TMSBr, which would yield the corresponding 
phosphonic acid of 12α. In hind-site, this modification could 
prove paramount in two ways. First, the anionic 1-phosphate 
of lipid A binds to positive patches on TLR4. The significance 
of this interaction has been established and is demonstrated 
by the previously mentioned mutagenesis studies and the 
attenuated endotoxicity of MPL (4). Second, the change in 
ionic character between the methyl protected and de-protected 
phosphonate substituent of 12α would potentially increase its 
solubility profile in aqueous media.            
 D-glucono-δ-lactone derivative 22 evaded the solubility 
issues compounds 11α, 11β, 12β, 13α, and 13β encountered from 
their inherent amphipathic nature. More importantly, compound 
22 demonstrated LPS antagonism in monocytic THP-1 cells, 
representing the first lactone monosaccharide R. sin-1 lipid 
A derivative to do so. Albeit, monosaccharide 22 does not 
inhibit LPS signaling as much as some disaccharide compounds 
like Eritoran (3). However, the comparative ease of synthesis 
could outweigh their differences of inhibition.  
 Overall, this embodiment of work provides new 
information regarding monosaccharide-based lipid A analogues. 
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Results from the studies herein provide a scientific basis 
for future investigations of lipid A antagonist, with added 
implications of inhibiting the adverse effects of septicemia. 
It is my hope that this work reveals structural insights of 
antagonistic properties to guide future explorations that 
ultimately lead to improved patient outcomes.   
 
 
V. Experimentals 
 
1. General Procedures 
 
 Glassware used for all experiments were oven-dried and 
all reactions were carried out under argon atmosphere unless 
otherwise mentioned.  All reaction solvents were purified 
prior to use: CH2Cl2 was dried by distillation over calcium 
hydride; THF was distilled over sodium. Reagent grade DMF and 
HPLC grade MeOH was obtained from Sigma-Aldrich and used 
without further purification.  
 NMR spectra were recorded at 600 MHz or 300 MHz. Chemical 
shifts (δ) for 1H and 13C spectra are expressed in ppm relative 
to internal standard (CDCl3: 7.26 for 1H and 77.23 for 13C). 
Chemical shifts for 31P were referenced with phosphoric acid 
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and then back calculated. Signals were abbreviated as s, 
singlet; d, doublet; dd, doublet of doublets; t, triplet; q, 
quartet; m, multiplet.  Thin layer chromatography (TLC) was 
carried out with pre-coated Merck F254 silica gel plates. 
Flash chromatography (FC) was carried out with Macherey-Nagel 
silica gel 60-230 mesh. Automated preparative chromatography 
was performed using a Biotage Isolera Prime or reverse phase 
C18 HPLC preparatory system.  
 
2. General Procedure for selective C4 ring opening of 4,6-O-
benzylidene 
 
 A stirred solution of 4,6-O-Benzylidene (0.1 mmol) in 
dry THF (0.66 mL) containing 4 Å molecular sieves was added 
NaCNBH3 (13.3 eq.). The reaction mixture was stirred for 5 
min. and subsequent addition of 2 N HCl/Et2O (13.3 eq.) was 
added in portions using a syringe over 10 min. The reaction 
was monitored by TLC until complete disappearance of starting 
material. The reaction mixture was then filtered through 
celite, diluted with DCM, washed with H2O (x1), HCO3- (x1), 
H2O (x1), dried over Na2SO4 and concentrated in vacuo. The 
residue was separated by preparative HPLC. 
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3. General Procedure for C6/C4 complete ring cleavage of 4,6-
O-benzylidene 
 
 4,6-O-Benzylidene (0.05 mmol) was dissolved in TFA and 
DCM (15% TFA in DCM, 0.7 mL) and stirred for 20 min. One drop 
of H2O was added and the reaction was stirred for 1 h. Reaction 
was monitored by TLC until complete and then concentrated in 
vacuo. The residue was azeotroped with toluene (1 mL x 4) and 
finally concentrated in vacuo. The residue was separated by 
preparative HPLC. 
 
Synthesis of 4,6-O-benzylidene-2,3-O-tetradecane-β-
thiophenol-D-glucopyranose (9) 
 
A stirred solution of 4,6-O-benzylidene-2,3-diol-β-
thiophenol-D-glucopyranose 87 (8) (9.15 g, 25.25 mmol) in dry 
DMF (18 mL) containing 4 Å molecular sieves was cooled to 
0˚C. A suspension of NaH (1.4g, 55.55 mmol) mixed in dry THF 
(12 mL) was added portion wise over 15 minutes. The reaction 
mixture was allowed to warm up to 40˚C and was stirred for 30 
minutes.  A catalytic amount of tetra-N-butylammonium iodide 
(0.933g, 2.52 mmol) was added to the mixture immediately 
O
OH
SPh
O
O NaH, DMF, RBr
R = C14H29
8
HO
Ph
O
OR
SPh
O
O
9
RO
Ph
	 68	
followed by dropwise addition of bromo-tetradecane (15.4 g, 
55.55 mmol) over 30 minutes. Reaction was monitored by TLC. 
After 24 hours, no further conversion of the starting material 
could be detected. The reaction mixture was cooled to 0˚C, 
diluted with CH2Cl2 (30 mL), quenched with NH4Cl, and washed 
with H2O (x 3). The organic phase was dried over Na2SO4, 
filtered and concentrated in vacuo. The residue was purified 
by column chromatography on silica gel (ethyl acetate-hexane 
gradient elution) to afford the title compound (9) (14.8 g, 
78%) as a white solid. (9): 1H NMR (600 MHz Chloroform-d) δ 
7.55 – 7.24 (m, 10H), 5.53 (s, 1H), 4.65 (d, J = 9.8 Hz, 1H), 
4.34 (dd, J = 10.5, 5.0 Hz, 1H), 3.84 (m, 1H), 3.76 (m, 3H), 
3.68 (m, 1H), 3.53 (m, 2H), 3.44 – 3.36 (m, 1H), 3.21 (dd, J 
= 9.7, 8.0 Hz, 1H), 1.66 – 1.50 (m, 10H), 1.42 – 1.18 (m, 
38H), 0.88 (t, J = 7.0 Hz, 6H). 
 
Synthesis of 4,6-diol-2,3-O-tetradecane-β-thiophenol-D-
glucopyranose (14)  
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Compound (14) was synthesized from (9, 100 mg, 0.133 mmol) 
using the general procedure 3 above (yield, 68.5 mg, 77%). 
(14): 1H NMR (600 MHz, Chloroform-d) δ 7.53 – 7.41 (m, 2H), 
7.33 – 7.23 (m, 3H), 4.62 (d, J = 9.7 Hz, 1H), 3.93 – 3.86 
(m, 2H), 3.83 – 3.72 (m, 2H), 3.70 – 3.62 (m, 2H), 3.52 – 
3.46 (m, 1H), 3.38 – 3.33 (m, 1H), 3.26 (t, J = 8.9 Hz, 1H), 
3.16 (t, 1H), 2.46 (s, 1H), 2.04 (s, 1H), 1.65 – 1.55 (m, 
4H), 1.48 – 1.05 (m, 44H), 0.88 (t, J = 7.0 Hz, 6H).13C NMR 
(151 MHz, Chloroform-d) δ 133.97, 131.68, 129.11, 127.64, 
107.49, 107.48, 87.98, 86.36, 81.20, 79.16, 73.97, 73.63, 
71.73, 70.65, 63.03, 32.08, 30.61, 30.51, 29.87, 29.85, 
29.83, 29.79, 29.72, 29.71, 29.53, 26.31, 26.28, 22.85. 
 
Synthesis of 6-O-benzyl-4-hydroxy-2,3-O-tetradecane-β- 
thiophenol-D-glucopyranose (15) 
 
Compound (15) was synthesized from (9, 100 mg, 0.133 mmol) 
using the general procedure 2 above (yield, 84.58 mg, 84%). 
(15): 1H NMR (300 MHz, Chloroform-d) δ 7.52 – 7.38 (m, 2H), 
7.29 – 7.14 (m, 8H), 4.50 (s, 2H), 3.83 – 3.53 (m, 6H), 3.51 
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– 3.33 (m, 2H), 3.26 – 3.01 (m, 2H), 2.60 (s, 1H), 1.61 – 
1.46 (m, 5H), 1.31 – 1.14 (m, 44H), 0.82 (t, J = 6.5 Hz, 6H). 
 
Synthesis of 4,6-O-benzylidene-2,3-O-tetradecane-α/β-D-
glucopyranose (10) 
 
Thio-glucoside (9) (1.022 g, 1.357 mmol) was dissolved in 
CH2Cl2 (14 mL) and the reaction mixture was stirred and cooled 
to 0˚ C. NIS (335.83 mg, 1.493 mmol 1.1 equiv.) and TFA 
(114.30 µL, 1.493 mmol, 1.1 equiv.) were added. The reaction 
was allowed to warm to room temp. After 1 h, the reaction 
mixture was cooled to 0˚ C, and piperidine (402.12 µL, 4.071 
mmol, 3 equiv.) was added. After 30 min, TLC analysis showed 
total conversion of the anomeric trifluoroacetate into a 
compound with a lower Rf (DCM/Hexanes 5:3, v/v, Rf 0.10). The 
reaction mixture was quenched by the subsequent addition of 
triethylamine (the reaction turned from dark red to yellow) 
and Na2S2O3 (aq., 20%, the yellow reaction mixture turned 
colorless). The reaction mixture was diluted with CH2Cl2, 
washed with H2O, dried with Na2SO4, filtered through celite, 
and concentrated in vacuo. Flash chromatography 
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(EtOAc:Hexanes 1.25:10, v/v, isocratic) afforded hemiacetal 
(10) as an anomeric mixture (α/β 1:1, 760.3 mg, 84%) as a 
white solid. (10): 1H NMR (300 MHz, Chloroform-d) δ 7.53 – 
7.43 (m, 2H), 7.42 – 7.30 (m, 3H), 5.54 (s, 1H), 5.30 (d, J 
= 3.8 Hz, 0.5H), 4.73 (d, J = 7.7 Hz, 0.5H), 4.36 – 4.27 (m, 
1H), 4.12 – 3.94 (m, 1H), 3.86 – 3.75 (m, 2H), 3.73 – 3.63 
(m, 3H), 3.61 – 3.44 (m, 2H), 3.43 – 3.34 (m, 1H), 3.12 (t, 
J = 8.0 Hz, 1H), 1.57 (s, 10H), 1.35 – 1.18 (m, 38H), 0.88 
(t, J = 6.5 Hz, 6H). 
 
Synthesis of 4,6-O-benzylidene-2,3-O-tetradecane-α/β-D-
methylene-dimethyl-phosphono-glucoside (11) 
 
A stirred solution of dry CH2Cl2:THF (12 mL, 1:3 respectively) 
and NaH (95% oil dispersion, 106.95 mg, 4.282 mmol, 1.5 eq.) 
was cooled to 0˚C. ((MeO)2(O)P)2CH2 (633.6 µL, 3.426 mmol, 1.2 
eq.) was added portion wise with a syringe over 15 minutes. 
The reaction mixture was allowed to warm up to room 
temperature and was stirred for 30 minutes. The reaction 
mixture was again cooled to 0˚C and (10) (1.877 g, 2.855 mmol) 
in dry CH2Cl2:THF (4 mL, 1:3 respectively) was added dropwise 
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via an addition funnel over 30 mins. The reaction mixture was 
allowed to warm up to room temperature and was monitored via 
HPLC. After 23 h, the reaction mixture was cooled to 0˚C, 
quenched with NH4Cl, diluted with CH2Cl2, washed with H2O (x1), 
HCO3- (aq. satd., x1), H2O (x1), dried with Na2SO4, filtered 
through celite, and concentrated in vacuo. Flash 
chromatography (EtOAc:Hexanes 1:4, v/v, isocratic) afforded 
(11) (1.104 g, 50.4%) as a white solid mixture of four 
diasteromers. The mixture was separated by preparative HPLC 
to afford; (11c-manno, 24.34 mg, 1.11%, Rf 4.331,); (7a-9a, 
351.11 mg, 16.03%, Rf 5.875); (11d-manno, 31.56 mg, 1.44%, Rf 
8.182); (15a-20a, 427.32 mg, 19.51%, Rf  8.353) white solids. 
(11c-manno): 1H NMR (600 MHz, Chloroform-d) δ 7.50 – 7.43 (m, 
2H), 7.38 – 7.28 (m, 3H), 5.60 (s, 1H), 4.47 (q, J = 7.7 Hz, 
1H), 4.20 (dd, J = 10.2, 4.6 Hz, 1H), 4.10 (t, J = 9.6 Hz, 
1H), 3.85 – 3.54 (m, 14H), 2.31 – 2.22 (m, 1H), 2.13 – 2.04 
(m, 1H), 1.66 – 1.55 (m, 5H), 1.38 – 1.22 (m, 45H), 0.88 (t, 
J = 6.7 Hz, 6H). 13C NMR (151 MHz, Chloroform-d) δ 137.74, 
128.87, 128.26, 126.10, 101.40, 79.06, 78.39, 78.32, 76.17, 
72.64, 71.99, 71.29, 69.07, 66.22, 52.90, 52.86, 52.68, 
52.64, 32.07, 30.18, 29.99, 29.86, 29.84, 29.82, 29.69, 
29.66, 29.52, 26.59, 26.27, 26.18, 25.66, 22.84, 14.27. 31P 
NMR (243 MHz, Chloroform-d) δ 30.32. (11α): 1H NMR (600 MHz, 
Chloroform-d) δ 7.52 – 7.44 (m, 2H), 7.39 – 7.29 (m, 3H), 
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5.58 (s, 1H), 4.24 (dd, J = 10.3, 4.9 Hz, 1H), 4.03 – 3.95 
(m, 2H), 3.92 – 3.87 (m, 1H), 3.81 (t, J = 10.3 Hz, 1H), 3.78 
– 3.69 (m, 7H), 3.63 – 3.58 (m, 1H), 3.56 – 3.48 (m, 2H), 
3.44 – 3.39 (m, 1H), 2.20 (ddd, J = 18.4, 6.3, 4.8 Hz, 2H), 
1.64 – 1.56 (m, 4H), 1.42 – 1.19 (m, 44H), 0.88 (t, J = 7.0 
Hz, 6H). 13C NMR (151 MHz, Chloroform-d) δ 137.77, 128.88, 
128.25, 126.15, 101.38, 81.10, 78.77, 74.84, 74.41, 72.01, 
71.71, 68.59, 52.87, 52.83, 52.29, 52.24, 32.08, 30.44, 
30.28, 29.88, 29.85, 29.83, 29.72, 29.65, 29.53, 27.95, 
27.01, 26.28, 26.25, 22.85, 14.28. 31P NMR (243 MHz, 
Chloroform-d) δ 31.67. (11d-manno): 1H NMR (600 MHz, 
Chloroform-d) δ 7.50 – 7.44 (m, 2H), 7.39 – 7.32 (m, 3H), 
5.53 (s, 1H), 4.57 – 4.51 (m, 1H), 4.25 (dd, J = 9.8, 4.3 Hz, 
1H), 3.80 – 3.70 (m, 7H), 3.69 – 3.60 (m, 4H), 3.58 – 3.52 
(m, 2H), 3.51 – 3.48 (m, 1H), 3.47 – 3.44 (m, 1H), 2.28 – 
2.18 (m, 2H), 1.65 (s, 1H), 1.59 – 1.51 (m, 4H), 1.37 – 1.22 
(m, 44H), 0.88 (t, J = 7.0 Hz, 6H). 13C NMR (151 MHz, 
Chloroform-d) δ 137.54, 128.99, 128.32, 126.10, 101.27, 
82.31, 79.66, 79.57, 78.68, 73.33, 72.26, 71.14, 71.10, 
69.45, 64.34, 52.60, 52.56, 52.52, 32.08, 30.47, 30.27, 
29.87, 29.84, 29.82, 29.80, 29.71, 29.66, 29.53, 26.29, 
26.26, 22.85, 14.28, 1.17. 31P NMR (243 MHz, Chloroform-d) δ 
32.76. (11β): 1H NMR (600 MHz, Chloroform-d) δ 7.49 – 7.45 
(m, 2H), 7.39 – 7.32 (m, 3H), 5.52 (s, 1H), 4.31 (dd, J = 
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10.3, 4.9 Hz, 1H), 3.91 – 3.85 (m, 2H), 3.76 – 3.71 (m, 6H), 
3.70 – 3.68 (m, 1H), 3.68 – 3.66 (m, 1H), 3.66 – 3.63 (m, 
1H), 3.55 – 3.48 (m, 3H), 3.46 – 3.42 (m, 1H), 3.05 (t, 1H), 
2.40 – 2.33 (m, 1H), 1.97 – 1.90 (m, 1H), 1.59 – 1.54 (m, 
4H), 1.31 – 1.20 (m, 44H), 0.88 (t, J = 7.0 Hz, 6H). 13C NMR 
(151 MHz, Chloroform-d) δ 137.54, 129.01, 128.34, 126.12, 
101.23, 83.19, 82.41, 82.32, 82.17, 75.39, 73.94, 73.47, 
70.64, 68.86, 52.67, 52.31, 32.09, 30.58, 30.54, 29.87, 
29.83, 29.72, 29.71, 29.53, 26.34, 26.32, 22.85, 14.29. 31P 
NMR (243 MHz, Chloroform-d) δ 31.83. 
 
Synthesis of 6-O-benzyl-4-hydroxy-2,3-O-tetradecane-α-D-
methylene-dimethyl-phosphono-glucoside (13α) 
 
Compound (13α) was synthesized from (11α, 100 mg, 0.1304 mmol) 
using the general procedure 2 above (yield, 92.27 mg, 92%). 
(13α): 1H NMR (300 MHz, Chloroform-d) δ 7.35 – 7.26 (m, 5H), 
4.89 (d, J = 10.8 Hz, 1H), 4.60 (d, J = 11.0 Hz, 1H), 3.98 – 
3.87 (m, 1H), 3.84 – 3.60 (m, 10H), 3.52 (t, J = 7.9 Hz, 2H), 
3.45 – 3.38 (m, 1H), 3.38 – 3.27 (m, 1H), 2.28 – 2.07 (m, 
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2H), 1.71 – 1.51 (m, 9H), 1.39 – 1.18 (m, 42H), 0.88 (t, J = 
6.5 Hz, 6H). 
 
Synthesis of 6-O-benzyl-4-hydroxy-2,3-O-tetradecane-β-D-
methylene-dimethyl-phosphono-glucoside (13β) 
 
Compound (13β) was synthesized from (11β, 35.6 mg, 0.0464 
mmol) using the general procedure 2 above (yield, 32.8 mg,  
92%).(13β): 1H NMR (600 MHz, Chloroform-d) δ 7.38 – 7.23 (m, 
5H), 4.58 – 4.52 (m, 2H), 3.83 – 3.75 (m, 2H), 3.75 – 3.65 
(m, 8H), 3.65 – 3.35 (m, 5H), 3.22 (t, J = 8.9 Hz, 1H), 2.96 
(t, J = 9.2 Hz, 1H), 2.65 (s, 1H), 2.36 – 2.29 (m, 1H), 1.96 
– 1.89 (m, 1H), 1.78 – 1.61 (m, 2H), 1.61 – 1.48 (m, 4H), 
1.48 – 1.07 (m, 42H), 0.87 (t, J = 7.0 Hz, 6H). 13C NMR (151 
MHz, Chloroform-d) δ 137.93, 128.54, 127.90, 86.43, 86.41, 
82.18, 82.09, 78.03, 74.81, 74.76, 73.73, 73.50, 72.12, 
70.45, 52.71, 52.67, 52.28, 52.24, 32.08, 30.65, 30.55, 
29.87, 29.85, 29.82, 29.80, 29.73, 29.72, 29.52, 28.54, 
27.59, 26.31, 22.85, 14.28. 31P NMR (243 MHz, Chloroform-d) δ 
32.20. 
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Synthesis of 4,6-diol-2,3-O-tetradecane-α-D-methylene-
dimethyl-phosphono-glucoside (12α) 
 
Compound (12α) was synthesized from (11α, 44 mg, 0.0574 mmol) 
using the general procedure 3 above (yield, 32.7 mg, 84%). 
(12α): 1H NMR (600 MHz, Chloroform-d) δ 3.91 – 3.58 (m, 13H), 
3.47 (q, J = 6.9 Hz, 1H), 3.43 – 3.39 (m, 1H), 3.37 – 3.32 
(m, 1H), 3.24 (dd, J = 9.4, 2.4 Hz, 1H), 2.49 (s, 1H), 2.27 
– 2.21 (m, 1H), 2.15 – 2.09 (m, 1H), 1.84 (s, 1H), 1.63 – 
1.54 (m, 4H), 1.44 – 1.09 (m, 44H), 0.87 (t, J = 7.0 Hz, 6H). 
13C NMR (151 MHz, Chloroform-d) δ 84.76, 79.77, 75.37, 75.31, 
73.68, 73.65, 70.24, 67.51, 63.28, 52.77, 52.72, 52.50, 
52.46, 32.07, 30.41, 30.11, 29.85, 29.83, 29.81, 29.80, 
29.77, 29.76, 29.65, 29.51, 28.03, 27.09, 26.29, 26.22, 
22.84, 14.27. 31P NMR (243 MHz, Chloroform-d) δ 31.84. 
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Synthesis of 4,6-diol-2,3-O-tetradecane-β-D-methylene-
dimethyl-phosphono-glucoside (12β) 
 
Compound (12β) was synthesized from (11β, 39 mg, 0.0508 mmol) 
using the general procedure 3 above (yield, 20.8 mg, 60%). 
(12β): 1H NMR (600 MHz, Chloroform-d) δ 3.84 – 3.69 (m, 10H), 
3.58 – 3.44 (m, 4H), 3.33 (dd, J = 7.4, 4.7 Hz, 1H), 3.23 (t, 
J = 9.0 Hz, 1H), 2.95 (t, J = 9.2 Hz, 1H), 2.35 – 2.28 (m, 
1H), 2.00 – 1.91 (m, 2H), 1.65 – 1.47 (m, 5H), 1.38 – 1.06 
(m, 44H), 0.93 – 0.79 (m, 6H). 13C NMR (151 MHz, Chloroform-
d) δ 86.43, 86.41, 82.62, 82.53, 79.71, 74.57, 74.52, 73.79, 
73.55, 71.07, 62.62, 52.74, 52.69, 52.61, 52.57, 32.07, 
30.65, 30.56, 29.86, 29.85, 29.82, 29.81, 29.79, 29.74, 
29.72, 29.52, 28.63, 27.68, 26.31, 26.30, 22.84, 14.27. 31P 
NMR (243 MHz, Chloroform-d) δ 32.47. 
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Synthesis of 4,6-O-benzylidene-2,3-O-tetradecane-D-glucono-
δ-lactone (21) 
 
A mixture of 4,6-O-benzylidene-2,3-O-tetradecane-α/β-D-
glucopyranose (10) (491.2 mg, 0.743 mmol), 
tetrapropylammonium perruthenate N(C3H7)4RuO4 (26.11 mg, 
0.0743 mmol), N-methyl-N-morpholine oxide (130.56 mg, 1.115 
mmol) and MS, 4 Å (0.57 g) in CH2Cl2 (19 mL) was stirred at 
room temperature for 2 h. Upon reaction completion, the 
mixture was diluted with DCM (50 mL) and washed with 5% sodium 
sulfite in brine, brine, and copper sulfate (10 mL, each). 
The combined organic extract was dried over Na2SO4, filtered 
through Celite, and concentrated in vacuo, and the 
concentrated residue was purified by silica column 
chromatography to afford (21) the title compound (416.49 mg, 
85%) as a white solid. (21): 1H NMR (300 MHz, Chloroform-d) δ 
7.53 – 7.45 (m, 2H), 7.42 – 7.33 (m, 3H), 5.58 (s, 1H), 4.56 
– 4.43 (m, 2H), 3.98 – 3.91 (m, 1H), 3.84 – 3.76 (m, 3H), 
3.75 – 3.55 (m, 4H), 1.62 – 1.55 (m, 4H), 1.25 (s, 44H), 0.88 
(t, J = 7.0, 5.9 Hz, 6H). 
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Synthesis of 6-O-benzyl-4-hydroxy-2,3-O-tetradecane-D-
glucono-δ-lactone (23) 
 
Compound (23) was synthesized from (21, 100 mg, 0.1517 mmol) 
using the general procedure 2 above (yield, 78.66 mg, 78%). 
(23): 1H NMR (300 MHz, Chloroform-d) δ 7.28 – 7.13 (m, 5H), 
4.46 (d, J = 2.0 Hz, 2H), 3.73 – 3.38 (m, 11H), 2.81 (s, 1H), 
2.53 (s, 1H), 1.54 – 1.38 (m, 4H), 1.14 (s, 42H), 0.76 (t, J 
= 6.0 Hz, 6H). 
 
Synthesis of 4,6-diol-2,3-O-tetradecane-D-glucono-δ-lactone 
(22) 
 
Compound (22) was synthesized from (21, 50 mg, 0.07587 mmol) 
using the general procedure 3 above (yield, 35.08 mg, 81%). 
(22): 1H NMR (300 MHz, Chloroform-d) δ 4.60 – 4.21 (m, 1H), 
4.11 (dd, J = 13.8, 4.8 Hz, 1H), 4.03 – 3.96 (m, 1H), 3.91 – 
3.60 (m, 6H), 3.60 – 3.32 (m, 2H), 3.15 (s, 1H), 2.18 (s, 
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1H), 1.65 – 1.53 (m, 4H), 1.25 (s, 46H), 0.88 (t, J = 6.5 Hz, 
6H). 
 
Synthesis of 6-O-benzyl-4-hydroxy-2,3-O-tetradecane-α- 
ethanethiol-D-glucopyranose (20) 
 
Compound (20) was synthesized from (18, 100 mg, 0.1418 mmol) 
using the general procedure 2 above (yield, 85.23 mg, 85%). 
(20): 1H NMR (300 MHz, Chloroform-d) δ 7.36 – 7.27 (m, 5H), 
4.57 (s, 2H), 4.37 (d, J = 9.6 Hz, 1H), 3.92 – 3.57 (m, 8H), 
3.52 – 3.40 (m, 2H), 3.23 (t, J = 8.6 Hz, 1H), 3.08 (t, J = 
9.2 Hz, 1H), 2.74 – 2.68 (m, 2H), 1.64 – 1.56 (m, 6H), 1.33 
– 1.24 (m, 44H), 0.88 (t, J = 6.5 Hz, 6H).  
 
Preparation of compounds for cellular treatment 
 
Lipid A derivatives were placed under hi-vacuum and weighed 
by difference using an analytical balance in solid form. Then, 
an appropriate volume of DMSO was added to the compounds to 
give a concentrated working stock solution for cellular 
treatment. The stock solution was serial diluted with DMSO to 
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afford the desired concentration range. The final DMSO 
concentration was maintained at 0.5%.   
 
LPS antagonistic activity assay and cell culture 
 
Human THP-1 cells that were in 1 mL aliquots and were stored 
in liquid nitrogen (Cane 4-level 1), were thawed and diluted 
1:10 in fresh growth medium and cultured in a T-75 flask. 
THP-1 growth medium was RPMI 1640 containing 10% FBS, 50 U/mL 
penicillin, 50 µg/mL streptomycin, 50µM β-mercapto-ethanol. 
THP-1 assay medium was the same as growth medium but with 
only 2% FBS. For cellular assays, THP-1 monocytes were 
centrifuged and resuspended to a cell concentration of 1*106 
cells/mL. LPS dilutions were conducted from 1 mg/mL UP LPS 
Invivogen Stock to achieve desired final concentration (see 
plate arrangement below). 96-well plate was then treated as 
follows: (1) Added 5µl of the LPS to some wells and added 
sterile water to the control wells, with 3 replicates for 
each concentration and 0.5% DMSO was used for control i.e. A 
(DMSO only) is added to wells A1, A2, and A3 triplicates with 
LPS and A4, A5, & A6 triplicates without LPS and so forth, 
(2) cells were incubated at 37ºC for 6 hours. After 6 hours, 
the entire solution from each well was removed, centrifuged 
for 10 mins to remove cells and the supernatant was placed in 
	 82	
Eppendorf tubes and frozen at -20ºC, (3) conducted ELISA to 
analyze secreted TNFα production. 
 
Plate arrangement:  
Final conc. µM LPS LPS LPS -LPS -LPS -LPS 
0 (DMSO only) A1 A2 A3 A4 A5 A6 
1 B1 B2 B3 B4 B5 B6 
3 C1 C2 C3 C4 C5 C6 
10 D1 D2 D3 D4 D5 D6 
30 E1 E2 E3 E4 E5 E6 
100 F1 F2 F3 F4 F5 F6 
 
TNFα ELISA 
Reagents: 
A. TNFα capture antibody: MAB610 (R&D Systems), 500 µg 
reconstituted in 1 ml PBS, 500 µg/ml, aliquots (50 µl) stored 
in –80 ºC freezer, diluted to 2 µg/ml in PBS for assay. 
B. TNFα detection antibody: BAF210 (R&D Systems), 
biotinylated, 50 µg reconstituted in 1 ml detection antibody 
diluent, 50 µg/ml, aliquots (50 µl) stored in –80 ºC freezer, 
diluted to 0.1 µg/ml for assay. 
C. TNFα recombinant protein (for standard curve): 210-TA 
(R&D Systems), 10 µg reconstituted in 10 ml standard diluent 
buffer.  Stored aliquots at -80 ºC after snap-freezing in 
EtOH/dry ice.  Diluted 0.5 ml to 5 ml (100 ng/ml) in standard 
diluent buffer.  
D. ELISA Buffers:  
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Wash; PBS containing 0.05% Tween 20 (5 ml 5% Tween 20, dilute 
with PBS to 500 ml); Sample Diluent, 20 mM Tris, pH 7.3 
containing 150 mM NaCl, 0.1% BSA, and 0.05% Tween 20; Blocking 
buffer, PBS containing 1% BSA, 5% sucrose, and 0.05% NaN3; 
Detection Antibody Diluent, 20 mM Tris, pH 7.3 containing 150 
mM NaCl and 0.1% BSA; Conjugate Diluent, PBS containing 1% 
BSA; Stop Solution, 1 M H2SO4, prepared from 96% stock. Diluted 
1:10 to make 1.8 M for assay; Standard Diluent, PBS containing 
0.1% BSA. 
 
Plate Preparation for ELISA 
Applied 100 µl capture antibody (2 µg/ml) to required wells. 
Sealed and incubated overnight at room temperature. Then 
washed x3 with wash buffer and applied 300 µl blocking buffer. 
Then incubated 1 h at room temperature followed by wash. 
 
ELISA Assay Procedure: 
Standard curve preparation – Diluted refrigerated standard 
(0.1 µg/ml) to 2000 pg/ml and performed serial dilutions in 
standard diluent buffer with 60 µl. 
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Then added 50 µl sample diluent buffer plus 50 µl standards 
and samples.  Used 50 µl H20 for 0 pg/ml standard and mixed 
by gently tapping plate.  Then sealed and incubated at room 
temperature for 2 h. Then washed 3x with wash buffer and added 
100 µl biotinylated detection antibody (0.1 µg/ml) and sealed 
and incubated for 2 h at room temperature. Then washed 3x 
with wash buffer and added 100 µl streptavidin HRP with 1/200 
dilution into conjugate diluent, sealed and incubated for 20 
min at room temperature. Then washed 3x with wash buffer and 
prepared substrate solution by mixing equal volumes of color 
reagent A & B within 15 minutes of use.  Then added 100 µl of 
substrate solution to each well and incubated for 30 minutes. 
Then added 50 µl stop solution and mixed by gently tapping. 
Then covered and read wells with absorbance plate reader at 
450 nm and at 630 nm to subtract out optical differences 
between wells. 
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